Alumis licenses ESK-001 to Kaken for Japan; $40M upfront/near-term plus $140M milestones

ALUMIS INC.

Alumis receives $20M upfront and $20M co-development payments from Kaken in 2025-2026.
Kaken gets exclusive rights to develop/commercialize ESK-001 for dermatology in Japan, with options for rheumatology and GI.
Alumis retains rights outside Japan; Kaken contributes to global development costs.
Cash runway extended through Phase 3 ONWARD psoriasis topline data readout.
Tiered royalties on Japan net sales: low double-digits to twenties percent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.